RE:RE:RE:RE:RE:Endo Files for Chapter 11Close enough Gudisgood.
Your approach was right and in general, the numbers tell the story. IMO.
Paladin was sold for 5-6x sales (if not mistaken) and the reasons were likely ...
1. high growth rate
2. large potential to grow the structure - more geographies
3. at peak of pharma cycle - high excitement and high valuations
And ...
We know Paladin has been stripped since - with many parts sold off.
Looking at quarterly sales - the business is in decline without a true rudder to grow that part of the business.
So ... not many who would take on that challenge due to the hard work required to grow a drug licensor in small markets.
Too many fail here.
Therefore - the selling price would likely be low on the x sales measure. Also a good time to sell and refocus on what ENDO really wants, bigger drugs with larger markets. With Goodman and Beaudet gone ... Paladin is not in Endo's wheelhouse.
IMO.